Comparative in vivo dissociation of Gadolinium Chelates in renally impaired rats: A relaxometry study

Investigative Radiology

Volumn 46, Issue 5, 2011, Pages 292-300

  Fretellier, Nathalie ^a   Idée, Jean Marc ^a   Dencausse, Anne ^a   Karroum, Oussama ^a   Guerret, Sylviane ^b   Poveda, Nicolas ^a   Jestin, Gaëlle ^a   Factor, Cécile ^a   Raynal, Isabelle ^a   Zamia, Philippe ^a   Port, Marc ^a   Corot, Claire ^a  

^a Research Division   (France)

^b Pathology Department   (France)

Author keywords

gadodiamide; gadolinium chelates; gadoterate; nephrogenic systemic fibrosis; relaxometry; renal impairment

Indexed keywords

CD34 ANTIGEN; CREATININE; GADODIAMIDE; GADOTERATE MEGLUMINE; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; CREATININE CLEARANCE; DISSOCIATION; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG TISSUE LEVEL; FEMUR EPIPHYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY DYSFUNCTION; MALE; MASS SPECTROMETRY; MATHEMATICAL VARIABLE; MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RAT; RELAXATION VARIABLE; RELAXIVITY CONSTANT; RELAXOMETRY; SKIN; SKIN BIOPSY; SKIN DEFECT; SKIN INFLAMMATION; SKIN NECROSIS; WISTAR RAT;

EID: 79954731621     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182056ccf     Document Type: Article

References (55)

1. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:710-712. (Pubitemid 46400200)
2. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27-30. (Pubitemid 44969309)
3. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. 2008;158:273-280.
4. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Am J Roentgenol. 2008;190:1-9.
5. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:968-975.
6. Thakral C, Abraham JL. Nephrogenic systemic fibrosis: histology and gadolinium detection. Radiol Clin North Am. 2009;47:841-853.
7. High WA, Ranville JF, Brown M, et al. Gadolinium deposition in nephro-genic systemic fibrosis: an examination of tissue using synchrotron X-ray fluorescence spectroscopy. J Am Acad Dermatol. 2010;62:38-44.
8. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21-26. (Pubitemid 46017000)
9. Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int. 2008;73:1413-1418. (Pubitemid 351770496)
10. Idée JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology. 2008;248:77-88.
11. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium-based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:73-76. (Pubitemid 46951248)
12. Perazella MA. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Semin Dial. 2008;21:150-154.
13. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis. A mechanistic hypothesis based on preclinical results from a rat model treated with gado-diamide. Exp Toxicol Pathol. 2009;61:537-552.
14. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
15. Fu LJ, Li JX, Yang XG, et al. Gadoliniumpromoted cell cycle progression with enhanced S-phase entry via activation of both ERK and PI3K signaling pathways in NIH 3T3 cells. J Biol Inorg Chem. 2009;14:219-227.
16. Stratta P, Canavese C, Aime S. Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibros-ing dermopathy. Curr Med Chem. 2008;15:1229-1235. (Pubitemid 351997809)
17. Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum. 2009;60:1508-1518.
18. Newton BB, Jiménez SA. Mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging. 2009;30:1277-1283.
19. Port M, Idée JM, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
20. Idée JM, Port M, Dencausse A, et al. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am. 2009;47:855-869.
21. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol. 2008;73:817-828.
22. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev. 1987;87:901-927.
23. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99: 2293-2352. (Pubitemid 30498114)
24. Chamberlain RM, Shirley DG. Time course of the renal functional response to partial nephrectomy: measurements in conscious rats. Exp Physiol. 2007; 92:251-262. (Pubitemid 46096269)
25. Fleck C, Appenroth D, Jonas P, et al. Suitability of 5/6 nephrectomy (5/6 NX) for the induction of interstitial renal fibrosis in rats. Influence of strain, sex, and surgical procedure. Exp Toxicol Pathol. 2006;57:195-205. (Pubitemid 43061190)
26. Crissman JW, Goodman DG, Hildebrandt PK, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol. 2004;32:126-131. (Pubitemid 38250001)
27. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44:226-233.
28. Grant D, Johnsen H, Juelsrud A, et al. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009;50:156-169.
29. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistri-bution and skin cellularity following a single injection of Omniscan in the rat. Invest. Radiol. 2010;45:507-512.
30. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging. 2007;26:1190-1197. (Pubitemid 350058285)
31. US Food and Drugs Administration CfDEaR. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005:1-27. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm078932.pdf. Accessed May 19, 2010.
32. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am. 2009;47:827-831.
33. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009;253:81-89.
34. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230-234.
35. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816.
36. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology. 2008;248:799-806.
37. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
38. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding the propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164-2173.
39. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724. (Pubitemid 41546838)
40. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228. (Pubitemid 44406182)
41. Stanisz GJ, Henkelman RM. Gd-DTPA relaxivity depends on macromolec-ular content. Magn Reson Med. 2000;44:665-667.
42. Port M, Corot C, Violas X, et al. How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol. 2005;40:565-573. (Pubitemid 41208633)
43. Laurent S, Vander Elst L, Copoix F, et al. Stability of MRI paramagnetic contrast media. A proton relaxometric protocol for transmetallation assessment. Invest Radiol. 2001;36:115-122. (Pubitemid 32147859)
44. Laurent S, Vander Elst L, Muller RN. Comparative study of the physico-chemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128-137.
45. 3+ ions. Contrast Media Mol Imaging. 2006;1:23-29.
46. Harrison A, Walker CA, Pereira KA, et al. Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids. Magn Reson Imaging. 1993;11:761-770.
47. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
48. Idee JM, Berthommier C, Goulas V, et al. Haemodynamic effects of macro-cyclic and linear gadolinium chelates in rats: role of calcium and transmet-allation. Biometals. 1998;11:113-123. (Pubitemid 28140331)
49. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. Invest Radiol. 2006;41:272-278. (Pubitemid 44406188)
50. Thakral C, Abraham JL. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol. 2009;36:1244-1254.
51. George SJ, Webb SM, Abraham JL, et al. Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol. 2010;163:1077-1081.
52. Evans CH. The occurrence and metabolism of lanthanides. In: Biochemistry of the Lanthanides. New York, NY: Plenum Press 1990, 285-337.
53. Steger-Hartmann T, Hofmeister R, Ernst R, et al. A review of preclinical safety data for Magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol. 2010;45:520-528.
54. DaSilva M, Deming MO, Fligiel SE, et al. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol. 2010;45:733-739.
55. Bhagavathula N, Dame MK, Dasilva M, et al. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol. 2010; 45:769-777.